Covaryx Cost Without Insurance: What Covaryx and Generic EEMT Cost, and Why the FDA Deadline Matters

By The HRT Index Editorial Team · Editorial research — not medically reviewed · Last updated November 3, 2026 · Last verified November 3, 2026

Covaryx cost without insurance is roughly $100 to $131 for 30 tablets with a free discount coupon, or $259 to $316 for a bottle of 100, in the price tools we checked on November 3, 2026. That works out to about $2.60 to $4.40 a tablet. Covaryx is not FDA-approved, and FDA has set May 4, 2027 as the effective date of a notice saying interstate shipment of covered products without an approved application is unlawful.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified · Last verified November 2026

• What we read on November 3, 2026: the Drugs.com price guides for Covaryx, Covaryx HS and esterified estrogens/methyltestosterone; the WebMDRx coupon pages for Covaryx and Covaryx HS; the Covaryx and Covaryx HS label and listing on DailyMed; FDA's Drugs@FDA database; and four Federal Register notices from FDA about estrogen-androgen combination products, published May 27, August 18, August 27 and October 30, 2026. We also read the 2019 Global Consensus Position Statement on testosterone for women and The Menopause Society's 2022 hormone therapy position statement. Every source is listed at the bottom.
• What we could not read: GoodRx and SingleCare blocked our automated checks, so we show no GoodRx or SingleCare prices.
• What we did not do: we did not fill a prescription, call a pharmacy to check stock, or check any insurer's formulary. The price at the counter is the only one that counts.
• Commercial interest: The HRT Index may earn a commission from some providers featured through The HRT Index's Find My HRT Path tool. No drug maker, pharmacy or discount card company paid for or reviewed this page, and this page links to no provider. See our affiliate disclosure.
• Verification Standard: we judge menopause care options on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency and access. Our methodology explains how.

Jump to: Prices · Monthly and yearly cost · Brand vs. EEMT · FDA status · The May 2027 deadline · Safety · Insurance and savings · Alternatives · Questions for your clinician · FAQ · Sources

Covaryx cost by strength and quantity: the dated prices

Covaryx comes in two strengths, and price tools list it both as the brand and under its generic name, esterified estrogens and methyltestosterone (often shortened to EEMT). On November 3, 2026, the lowest coupon prices we found were about $100 for 30 Covaryx HS tablets and about $130 for 30 full-strength EEMT tablets, and Drugs.com listed 100-tablet bottles from $259.27.

What is in each tablet (from the DailyMed label):

• Covaryx: 1.25 mg esterified estrogens and 2.5 mg methyltestosterone. Light yellow tablet marked "C010".
• Covaryx HS (half strength): 0.625 mg esterified estrogens and 1.25 mg methyltestosterone. Light pink tablet marked "C020".
• Both come in bottles of 100 tablets.

Cash and coupon prices read November 3, 2026. Prices vary by pharmacy, location and day.

How to read the table:

• A coupon can cut the shelf price by about 43%. WebMDRx showed CVS's regular price for 30 Covaryx HS tablets as $201.03 and its coupon price as $113.99. For 30 EEMT tablets at Walgreens, it was $231.13 before the coupon and $131.06 with it.
• A 100-tablet bottle was cheaper per tablet in our check. Drugs.com's lowest 100-tablet prices worked out to $2.59 to $3.16 a tablet. The 30-tablet coupon prices worked out to $3.33 to $4.37.
• Strength barely changes the price. Drugs.com listed the same $315.50 for 100 tablets of either Covaryx strength, and the same range for either EEMT strength.
• Location matters. WebMDRx prices were for its default ZIP code (33186), and Drugs.com does not say which location its prices are for. Expect different numbers near you.

Covaryx is far more expensive than plain generic estrogen. In our estradiol cost without insurance check on October 27, 2026, 30 generic estradiol tablets cost $10.24 to $12.57 with a GoodRx coupon in Denver. That's not a reason to switch on its own, because the two medicines are not the same. It's a reason to ask your clinician whether Covaryx is still the right fit.

What Covaryx costs per month and per year

What you pay each month depends on how many tablets your prescription calls for. At the prices above, a month of Covaryx usually comes to about $55 to $120 for one tablet a day, and about double that for two Covaryx HS tablets a day.

The label gives a usual dose of 1 Covaryx tablet, or 1 to 2 Covaryx HS tablets, a day. It says to give the tablets cyclically, for example three weeks on and one week off, at the lowest dose that controls symptoms. Your prescriber decides your actual dose and schedule. The rows below are examples for budgeting, not dosing advice.

Our arithmetic on November 3, 2026 prices. Not quotes.

A year at 1 tablet a day, 3 weeks on and 1 week off (13 four-week cycles, 273 tablets): about $708 at $2.59 a tablet, $861 at $3.16 a tablet and $909 at $3.33 a tablet. These totals are per-tablet math. You'd actually buy whole bottles, and prices will change during the year.

How long a 100-tablet bottle lasts: about 19 weeks at 21 tablets per 4 weeks, or about 14 weeks at 28.

The medicine is only part of the cost. You also need a prescriber, and the Covaryx label says to check liver function tests periodically because of the methyltestosterone. Ask what visits and lab tests will cost before you budget.

The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult. It's free, asks 5 quick questions, takes about 60 seconds and needs no email. It is not a diagnosis or a treatment plan.

Covaryx vs. generic EEMT: is there a cheaper generic?

Yes, tablets with the same two ingredients are sold under the generic name esterified estrogens and methyltestosterone, and Drugs.com's lowest 100-tablet price for them ($259.27) was below its Covaryx price ($315.50). But "generic" means something different here than it does for most medicines.

For an FDA-approved drug, a generic has been reviewed by FDA against the original. No esterified estrogens and methyltestosterone tablet, brand or generic, has FDA approval. We searched Drugs@FDA on November 3, 2026: it lists esterified estrogens products and methyltestosterone products on their own, but no approved product combining the two.

So Covaryx, Covaryx HS, EEMT, Estratest and other versions are all marketed without FDA approval. DailyMed lists labels for many of them. Before you switch versions to save money, ask your prescriber and pharmacist whether the strengths match and whether the switch makes sense for you.

Names you may see for the same combination:

Is Covaryx FDA-approved?

No. Covaryx is not FDA-approved. Its DailyMed listing gives its marketing category as "unapproved drug other" and carries this disclaimer: "This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA." The label itself says the product "has not obtained FDA pre-market approval applicable for new drugs."

That surprises many women, because Covaryx is a prescription tablet sold at ordinary pharmacies. Here's the short history, from FDA's May 27, 2026 Federal Register notice:

"Vasomotor symptoms" means hot flashes and night sweats. The Covaryx label still lists that use, for women whose symptoms did not improve on estrogen alone. FDA's 2026 finding is that this use has not been shown to be effective.

The FDA deadline: what May 4, 2027 means for your Covaryx cost

FDA's May 2026 notice says that once it takes effect, shipping these products across state lines without an approved new drug application or abbreviated new drug application is unlawful, and that FDA intends to take enforcement action without further notice. FDA has pushed the effective date back three times. The current date is May 4, 2027.

Each time, FDA said it needed more time to consider issues raised by interested parties. So the date could move again, or it could hold.

Does it cover Covaryx? The notice covers estrogen-androgen fixed-combination products and any "identical, related, or similar" product. Its background names esterified estrogens with methyltestosterone, the combination in Covaryx. FDA says anyone who wants to know whether a specific product is covered can write to the agency.

What it could mean for you:

• Supply may get harder to find. The notice tells companies how to report discontinued products. We did not check pharmacy stock, and we can't predict what any company will do.
• Prices could change. We have no sourced forecast, so we're not guessing at one. We'll update this page when we recheck.
• You have time to plan, but don't wait for the last refill. Talk with your prescriber now about what you'll do if Covaryx or EEMT becomes unavailable. Don't stop or change a hormone medicine on your own.

Covaryx safety: what the label says before you pay for a refill

The Covaryx label contains the warnings of an older estrogen label plus warnings specific to methyltestosterone, an oral form of testosterone. Two matter most for cost planning: the liver warnings that call for periodic blood tests, and the fact that the tablets contain no progestin.

From the Covaryx label (DailyMed, label revised January 2020):

• Boxed warnings. The label says estrogens have been reported to increase the risk of endometrial cancer (cancer of the uterine lining) and should not be used during pregnancy. It also includes the Women's Health Initiative findings of higher risks of heart attack, stroke, invasive breast cancer, and blood clots in the lungs and legs with a different estrogen-plus-progestin product.
• No progestin. The label says Covaryx "do[es] not contain a progestin." It tells prescribers to watch women with a uterus closely for signs of endometrial cancer. The Menopause Society's 2022 position statement says women with a uterus using systemic estrogen should receive adequate progestogen (a progesterone-type medicine), apart from one specific combination product. Ask your clinician whether that applies to you. See do you need progesterone if you have a uterus.
• Liver. The label warns that prolonged high doses of androgens have been linked to peliosis hepatis (blood-filled cysts in the liver), which "can be a life-threatening or fatal complication," and to liver tumors. It also says cholestatic hepatitis and jaundice can occur with this type of androgen "at a relatively low dose." It says liver function tests should be done periodically.
• Cholesterol and other blood fats. The label lists increased serum cholesterol among the androgen side effects, and increased triglycerides among the estrogen effects on lab tests. The 2019 Global Consensus Position Statement on testosterone for women says oral testosterone is linked to unfavorable changes in HDL and LDL cholesterol "and is not recommended."
• Masculinizing effects. The label says to watch for a deeper voice, extra facial or body hair, acne and enlargement of the clitoris, and that stopping at the first mild signs is needed to prevent permanent changes.
• Who should not take it, according to the label: anyone with known or suspected breast cancer (except certain metastatic cases) or an estrogen-dependent cancer, known or suspected pregnancy, undiagnosed abnormal genital bleeding, active blood clots or a past history of clots tied to estrogen use, severe liver damage, or who is breastfeeding.

About the 2026 label changes. On February 12, 2026, FDA approved labeling changes for six approved menopause hormone products that removed some boxed-warning statements. Covaryx's label is not FDA-approved labeling, and the DailyMed version we read was last revised in January 2020. See our FDA HRT label change 2026 guide for which approved products changed.

Testosterone for women in the U.S. FDA's August 18, 2026 Federal Register notice for its workshop on testosterone in menopausal women says: "Unlike estrogen-containing products, there are no FDA approved indications for testosterone therapy for menopausal women." The 2019 Global Consensus Position Statement says the only evidence-based reason to use testosterone in women is hypoactive sexual desire disorder (HSDD), meaning low sexual desire that causes distress. The DailyMed listing shows Covaryx as a Schedule III controlled substance (CIII), so it needs a prescription and refills are more tightly controlled. For more, see testosterone for women dosage and our HRT side effects guide.

Does insurance cover Covaryx, and are there savings programs?

We could not confirm coverage for any plan, so check your own formulary. Ask your plan directly whether it covers Covaryx, Covaryx HS or esterified estrogens/methyltestosterone, and at what tier. We did not check any insurer's formulary for this page.

• Manufacturer savings: on November 3, 2026, Drugs.com said it found no manufacturer promotions for Covaryx, Covaryx HS or esterified estrogens/methyltestosterone, and it listed no patient assistance program for Covaryx.
• Free discount cards: coupon prices like the WebMDRx ones above are free to use. They take the place of insurance for that fill and don't stack with it. Our HRT prescription discount card guide explains how they work.
• Mail order: we did not find esterified estrogens/methyltestosterone in Cost Plus Drugs' medication search on November 3, 2026. Our Cost Plus Drugs HRT guide covers what it does carry.
• HSA and FSA: prescription medicines are generally eligible expenses. Check your plan's rules and keep the receipt.

For coverage of other hormone medicines, see does insurance cover HRT for menopause and does insurance cover testosterone for women.

What women on Covaryx often discuss with their clinician instead

If cost, the FDA deadline or the label's warnings make you rethink Covaryx, the useful next step is a conversation with your prescriber, not a switch on your own. The options below are what menopause care usually compares. Which one fits you is a medical decision.

What the evidence says about the testosterone part. The 2019 Global Consensus Position Statement says that where no approved female product exists, prescribing an approved men's product at a female dose is reasonable if blood levels stay in the normal female range. It says oral testosterone is not recommended, and it says compounded testosterone "cannot be recommended" for HSDD unless an authorized equivalent isn't available. See oral vs. transdermal estrogen for how pills and skin products differ for estrogen, and compounded vs. FDA-approved HRT for the approval question.

If the reason you were prescribed Covaryx was low desire, a clinician who focuses on menopause and sexual health can help sort out the cause. See best online menopause clinic for low libido.

If you're not sure where to start, Find My HRT Path asks about your symptoms, what you've tried, your age, your state and your health history. Then it shows a featured care option, or tells you when online care isn't the right place to start.

Questions to ask before your next Covaryx refill

Take these to your prescriber or pharmacist. They turn a price question into a plan.

1. Why am I on Covaryx, and is that still the goal? Hot flashes, low desire or something else?
2. What's the plan if Covaryx or EEMT becomes hard to get after FDA's May 4, 2027 date?
3. Is a 100-tablet bottle cheaper for me than 30 at a time? Can my prescription allow it?
4. Do I need a progestogen with this if I have a uterus?
5. When are my next liver function tests and cholesterol check, and what do they cost?
6. Would an FDA-approved estrogen, with or without a separately prescribed testosterone, fit my situation?
7. Is the EEMT version my pharmacy stocks the same strength as my Covaryx?

Who should see an in-person clinician first?

Price should never decide whether a hormone is safe for you. See a clinician in person before starting, changing or stopping Covaryx if you have unexplained vaginal bleeding, a history of breast or uterine cancer, blood clots, stroke, heart attack or liver disease, yellowing of your skin or eyes, or if you might be pregnant. Find My HRT Path flags situations like these and points you to guidance instead of an online visit when that's the safer start.

Find the route that fits you

If you're weighing Covaryx's cost against other options, start with your situation. Find My HRT Path is free and takes about 60 seconds. It shows a featured care option, or tells you when online care isn't the right place to start.

Frequently asked questions about Covaryx cost

How much does Covaryx cost without insurance?

On November 3, 2026, WebMDRx showed 30 Covaryx HS tablets for $99.92 to $113.99 with its free coupon, and Drugs.com listed 100 Covaryx tablets for $315.50. Prices vary by pharmacy and location.

What does Covaryx cost per month?

At one tablet a day for three weeks out of four, about $55 to $70 a month at the per-tablet prices we found. At one tablet every day, about $73 to $93. Your prescription decides how many tablets you need.

Is there a generic for Covaryx?

Tablets with the same ingredients are sold as esterified estrogens and methyltestosterone, or EEMT. Drugs.com listed them from $259.27 for 100 tablets. None of these versions, brand or generic, is FDA-approved.

Is Covaryx FDA-approved?

No. DailyMed lists Covaryx as an "unapproved drug," and its label says it has not obtained FDA pre-market approval. In May 2026, FDA concluded these estrogen-androgen combinations have not been shown to be effective for their labeled use.

Is Covaryx being discontinued?

We don't know of any announced discontinuation. FDA has said shipping these products across state lines without an approved application becomes unlawful on the notice's effective date, now May 4, 2027. That date has already moved three times.

What's the difference between Covaryx and Covaryx HS?

Covaryx HS is half strength: 0.625 mg esterified estrogens and 1.25 mg methyltestosterone, against 1.25 mg and 2.5 mg in Covaryx. Drugs.com listed both at $315.50 for 100 tablets.

Is Covaryx the same as Estratest?

Both contain esterified estrogens and methyltestosterone in the same two strength pairs, and DailyMed lists both as unapproved. Ask your pharmacist before treating one as a substitute for the other.

Is there a Covaryx coupon or savings card?

Drugs.com said it found no manufacturer promotions for Covaryx or its generic versions on November 3, 2026. Free pharmacy discount cards showed coupon prices around 43% below the regular price in our check.

Is Covaryx a controlled substance?

Yes. Its DailyMed listing shows DEA Schedule CIII, because it contains methyltestosterone. It needs a prescription.

Does insurance cover Covaryx?

It depends on your plan. Ask whether Covaryx or esterified estrogens/methyltestosterone is on your formulary. We did not check any insurer's coverage.

How we checked this page, and its limits

This is editorial research and is not medical advice. It is not medically reviewed (medical review policy). A clinician who knows your history should decide what you take. If we get something wrong, tell us.

Limits:

• WebMDRx coupon prices are for its default location, ZIP 33186, read November 3, 2026. Drugs.com cash prices were read the same day; Drugs.com does not name a location. GoodRx and SingleCare blocked our automated checks, so their prices are not included.
• Monthly and yearly figures are our arithmetic on one day's prices, using example schedules. They are not quotes or dosing advice.
• We did not check pharmacy stock, any insurer's formulary, or a company's plans for the product.
• FDA's effective date has changed three times in 2026. We'll recheck it.

Sources (all read November 3, 2026):

• U.S. National Library of Medicine, DailyMed. Covaryx and Covaryx HS (esterified estrogens and methyltestosterone) label and listing.
• U.S. National Library of Medicine, DailyMed. Estratest FS and Estratest HS label and listing.
• U.S. Food and Drug Administration. Drugs@FDA, searched for esterified estrogens and methyltestosterone products.
• U.S. Food and Drug Administration, Federal Register, May 27, 2026. Estrogen-androgen fixed-combination drug products; final resolution of DESI 7661.
• U.S. Food and Drug Administration, Federal Register, August 27, 2026. Second extension of effective date.
• U.S. Food and Drug Administration, Federal Register, October 30, 2026. Third extension of effective date, to May 4, 2027.
• U.S. Food and Drug Administration, Federal Register, August 18, 2026. Testosterone use in menopausal women; public workshop.
• Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism, 2019.
• The Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society.
• Drugs.com price guides: Covaryx, Covaryx HS and esterified estrogens/methyltestosterone.
• WebMDRx coupon pages: Covaryx and Covaryx HS.

Questions about our process: methodology, editorial standards and affiliate disclosure.